**Abstract.** The aim of the present study was to investigate the effect of fatty acid synthase complex (FASN) on the migration capacity of bladder transitional cell carcinoma (BTCC) cells and the involvement of matrix metalloproteinase-9 (MMP-9) via targeting of phospho-AKT (p-AKT). FASN-specific small-interfering RNA (FASN-siRNA) was used to inhibit FASN gene expression in the 5637 and 253J BTCC cell lines. The knockdown efficiency of FAM-conjugated FASN-siRNA was confirmed by fluorescence microscopy. The migratory abilities of BTCC cells were assessed using a Transwell assay. Furthermore, protein and mRNA expression of FASN, p-AKT, AKT, and migration-associated protein MMP-9 were detected by western blot analysis. Treatment with FASN inhibitor Cer and FASN-siRNA decreased the migratory capacity of bladder cancer cells and reduced the levels of p-AKT as well as the expression of MMP-9. These results indicated that FASN inhibition suppressed the migratory capacity of BTCC cells through suppressing AKT activation and consequently reducing MMP-9 expression. Targeting FASN may represent a promising novel therapeutic strategy for BTCC.

**Introduction**

As the second most common type of genitourinary malignancy along with urothelial cancer, bladder cancer comprises 90% of all primary bladder cancers (1). In spite of the advances in chemotherapy and surgical techniques for this cancer type, ~50% of bladder cancer patients develop metastases and succumb to the disease (2). As targeted agents have had limited success in treating metastatic bladder cancer (3-5), the development of treatments with an enhanced ability to reduce the migratory capacity of bladder transitional cell carcinoma (BTCC) is urgently required.

Fatty acid synthase complex (FASN), which was discovered in 1994 by Kuhajda et al (6), is the only human protein with the ability to catalyze a reductive de novo synthesis of long-chain fatty acids from acetyl-coenzyme A (CoA) and malonyl-CoA using nicotinamide adenine dinucleotide phosphate (6). In most normal tissue types, except for adipose and liver tissues, FASN expression is low (6,7). In addition, FASN is highly expressed in most types of human carcinoma and its inhibition may therefore hold promise as a strategy for cancer chemoprevention (8). Of note, selective inhibition of FASN has been used for lung cancer treatment (9). Thus, current research on the discovery of novel diagnostic tools and treatment methods for cancer focuses on fatty acid metabolism and the role of FASN in cancer (10). A previous study by our group has reported high levels of FASN expression in BTCC, and revealed that inhibition of FASN suppressed phosphorylated AKT (p-AKT) and induced apoptosis in bladder cancer (11). However, to the best of our knowledge, the possible role of FASN in the migratory capacity of BTCC cells has not yet been assessed. The present study therefore examined the effects of FASN-specific small-interfering RNA (FASN-siRNA) and FASN inhibitor cerulenin (Cer) on BTCC-cell migration. Furthermore, the effects of FASN knockdown on the AKT pathway and the expression of matrix metalloproteinase (MMP)-9 were investigated in order to assess the molecular mechanism of the role of FASN in BTCC-cell migration. The present study revealed the implication of FASN in the migratory capacity of BTCC cells as well as an underlying mechanism, and indicated that targeting of FASN may represent a novel therapeutic strategy for BTCC.

**Materials and methods**

**Cell culture and reagents.** The 5637 and 253J bladder transitional cell carcinoma lines were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂ in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific,
Inc.), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.). Cells in the logarithmic growth phase were used in all experiments. Cer was obtained from Biomol (Enzo Life Sciences, Farmingdale, NY, USA) and kept in a 10 mg/ml stock solution in dimethyl sulfoxide (Gibco; Thermo Fisher Scientific, Inc.).

**siRNA and siRNA transfection.** Using the nucleotide sequence of the FASN gene from GenBank (http://www.ncbi.nlm.nih.gov/genbank/; no. 004104 NM), siRNA to target FASN was designed (5’-CCCAGGCUGAGUUUACAATT-3’). Furthermore, a negative control siRNA sequence (5’-UUCUCCAACGUGUCAGUTT-3’), named as Negative-siRNA, was designed. All siRNAs were designed and synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). The 5637 and 253J cells were plated in six-well plates (2 ml medium/well) to reach ~70% confluency at the time-point of transfection. Cells were transfected with FASN-siRNA in the experimental group, and with Negative-siRNA in the negative control group using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. After 12 h of transfection, cells were cultured in RPMI 1640 medium. To assess the transfection efficiency, FAM-siRNA (Shanghai GenePharma Co., Ltd.) was analyzed by fluorescence microscopy (BX50; Olympus Corporation, Tokyo, Japan).

**Reverse transcription-quantitative polymerase chain reaction.** Total RNA from cells were prepared using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA was reverse-transcribed using an AMV Reverse Transcription System (Promega Corporation, Madison, WI, USA) and was amplified RT-qPCR. The sequences of the primers were as follows: FASN (sense, 5’-TATGGCTTCTTCGTGCAGCAGTT-3’; antisense, 5’-GCTGACCACAGCTCTCAG-3’). The Ct values were normalized to the reference gene β-actin (sense, 5’-CGGGAAATCGTGCGTA-3’; antisense, 5’-TGCCCCAGGAAGGAAGCT-3’) and amplification was performed using SYBR Green as the fluorescent dye (Takara Biotechnology Co., Ltd., Dalian, China). The specificity of the PCR products was assessed with melting-curve analysis. The relative expression of mRNA was calculated using the comparative delta ∆∆Cq. (quantification cycle) method (12) to compare the expression levels among different samples.

**Western blot analysis.** Following transfection with FASN-siRNA for 48 h or treatment with Cer (5 or 10 µg/ml) for 24 h in six-well plates, cells were harvested and re-suspended in 60 µl lysis buffer (Gibco; Thermo Fisher Scientific, Inc.) and the protein concentration was determined via the Bicinchoninic Acid Protein kit (Beyotime Institute of Biotechnology, Inc.). 30-µg aliquots were separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Gibco; Thermo Fisher Scientific, Inc.), followed by electrotransfer at 100 V onto a polyvinylidene fluoride membrane (Roche, Basel, Switzerland). Subsequent to blocking with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween 20 (TBST; Gibco; Thermo Fisher Scientific, Inc.) for 2 h at room temperature, the membrane was incubated with the following rabbit monoclonal primary antibodies at 4˚C overnight: Anti-FASN (cat. no. 3189; 1:1,000), total-AKT (cat. no. 4691; 1:1,000), p-AKT (cat. no. 4060; 1:1,000), MMP-9 (cat. no. 3852; 1:1,000) or β-actin (cat. no. 4970; 1:1,000); Cell Signaling Technology, Danvers, MA, USA). Following three washes in TBST for 10 min each, the blots were incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G at 1:2,000 dilution (cat. no. 7074; Cell Signaling Technology) for 2 h at room temperature. Antigen was detected using standard chemical luminescence methodology. Immune complexes were visualized using an enhanced chemiluminescence kit (EMD Millipore, Billerica, MA, USA) and exposure to Biomax film (Kodak, Rochester, NY, USA).

![Figure 1. Transfection of 5637 and 253J bladder cancer cells with FASN siRNA.](image)
Transwell assay. Cell migration was assessed using Transwell plates (pore size, 8 µm; Costar; Corning Inc., Corning, NY, USA). Following transfection with FASN-siRNA for 48 h or treatment with 3 µg/ml Cer for 24 h, 5637 and 253J cells were washed once with phosphate-buffered saline (PBS). 200 ml serum-free RPMI 1640 medium containing 1x10^5 cells and 3 µg/ml Cer in the Cer treatment group was placed in the upper chamber, and the lower chamber was filled with 500 ml of the same medium. Subsequent to incubation of the plates for 24 h at 37°C, cells on the upper side of the filters were removed with cotton-tipped swabs. Following fixing in methanol (Gibco; Thermo Fisher Scientific, Inc.), cells on the lower side of the filter were stained with 0.1% of crystal violet in PBS (Gibco; Thermo Fisher Scientific, Inc.). The number of migrated cells was quantified in six random high-power microscopic fields per sample (BX50; Olympus Corporation). Transwell assays were performed in triplicate.

Statistical analysis. SPSS 18.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used to analyze all data. Values
are expressed as the mean ± standard error of the mean. Comparisons between two groups were performed using Student's t-test and the χ²-test was utilized to assess statistical significance between categorical data. P<0.05 was considered to indicate a statistically significant difference between values.

Results

siRNA-mediated FASN knockdown. According to a previous study by our group evaluating three different siRNA sequences targeting FASN (11), the most efficient of these siRNAs was used in the present study to knockdown FASN expression in 5637 and 253J cells. To determine the transfection efficiency, 5637 and 253J cells were transfected with FAM-siRNA for 12 h respectively and FAM fluorescence was detected by fluorescence microscopy (Fig. 1A). The amount of positively transfected cells observed visually to exceed 70%. To assess the knockdown efficiency of FASN-siRNA in 5637 and 253J cells, mRNA and protein expression were detected using RT-qPCR and western blot analysis (Fig. 1B and C). Transfection with FASN-siRNA resulted in a significant reduction of FASN mRNA and protein expression in the BTCC cell lines. These results indicated that FASN-siRNA was successfully transfected into 5637 and 253J cells and efficiently knocked down FASN.

FASN inhibition by Cer and FASN-siRNA suppresses the migratory capacity of BTCC cells. The present study assessed whether inhibition of FASN expression affected the migration of 5637 and 253J cells using a Transwell assay. Treatment with 3 µg/ml Cer for 24 h or transfection with FASN-siRNA for 48 h significantly decreased the percentage of 5637 and 253J cells that had transgressed through the Transwell filter (Fig. 2A-C). The results therefore indicated that FASN inhibition suppressed BTCC-cell migration.

FASN inhibition de-activates AKT and reduces MMP-9 expression. To identify the mechanism by which FASN inhibition reduced the migratory capacity of BTCC cells, two key regulatory factors of cell-migration, MMP-9 and AKT, were assessed. MMP-9, an important indicator of tumor microenvironment, has been shown to be involved in the migratory capacity of bladder cancer cells (13,14). Furthermore, the phosphoinositide-3 kinase (PI3K)/AKT pathway is one of the most important signaling pathways and can regulate migration and invasion of bladder cancer cells (15,16). Following transient transfection of 5637 and 253J cells with siRNA for 48 h or treatment with 5 and 10 µg/ml Cer for 24 h, the protein levels of MMP-9 and p-AKT were found to be reduced (Fig. 3A and B). However, Cer did not affect FASN expression in these cell lines (Fig. 3A).

Discussion

The natural product Cer is a mycotoxin which was initially developed as an anti-fungal agent and is now widely used as a natural inhibitor of FASN activity (17,18). Furthermore, transfection with siRNA is a commonly used method for silencing the expression of specific genes (19). In the present study, FASN-siRNA and FASN inhibitor Cer were used to inhibit FASN expression in the 5637 and 253J BTCC cell lines, which led to a decrease in the cells' migratory potential. This was accompanied by decreases in MMP-9 expression and p-AKT levels, indicating that FASN inhibitor Cer and FASN-siRNA reduced the migratory capacity of BTCC cells via suppressing the activation of AKT, leading to a downregulation of MMP-9 expression.

The role of FASN in cancer has become a focus of current research on the discovery of novel diagnostic tools and treatments for cancer. FASN expression and sensitivity to FASN-targeting drugs are directly linked to cell growth, while only being indirectly correlated with transformation, differentiation and senescence in various cancer types, including breast (20), prostate (21), ovarian (22), lung (23) and liver cancer (24). In addition, FASN was also found to be involved in cancer occurrence (25), progression (26), metastasis (27) and chemotherapeutic resistance (28) in various types of cancer. FASN is therefore a metabolic marker of cell proliferation as well as a useful target for future drug development.

Previous studies indicated that FASN is correlated with metastasis in several types of tumor cell (29,30). However, in BTCC cells, the regulatory function of FASN on the migratory capacity and the detailed underlying mechanisms have remained elusive. The present study assessed the effects of FASN inhibition on the expression of MMP-9, which is able to promote cell migration, in human BTCC cells. The observed reduction of MMP-9 expression was likely to be based on the simultaneous suppression of p-AKT. Therefore, inhibition of FASN suppresses the migratory capacity of BTCC cells, at least in part, by de-activating p-AKT. These results indicated that FASN may be a potential target for BTCC therapy.

Cancer metastasis, which is the main cause of mortality in cancer patients, is a complex multi-step process facilitated by several molecular key events. Identifying and targeting various associated genes is the most promising strategy to treat or prevent metastasis (2,31,32). MMPs are a family of zinc-dependent endopeptidases which participate in the proteolytic destruction of basement and extracellular matrix membranes, therefore being essential for tumor invasion and metastasis (33,34). Among them, MMP-9 is one of the most important markers of cancer invasion and metastasis (35). A previous study has shown that MMP-9 is implicated in metastasis of bladder cancer (36). In addition, MMP-9 was shown to be associated with the pathological grade, clinical stage and prognosis of tumors (37-39). Therefore, the present study assessed whether FASN inhibition regulates MMP-9 expression and found that the protein levels of MMP-9 were significantly downregulated.

In recent years, the PI3K/AKT signaling pathway has attracted broad scientific and clinical interest as a cancer drug target (40,41). It is thought that activation of the PI3K/AKT signaling pathway is associated with invasion and metastasis of cancer cells (42,43). The activated form of AKT, p-AKT, has a vital role in cell-cycle progression, the apoptotic program and the migratory capacity of cells via downregulating the expression of caspase 3 and upregulating MMP-9 (44). Therefore, inhibition of the PI3K/AKT pathway is regarded as a potential strategy for the treatment of cancer (45,46). In addition, FASN inhibition was shown to decrease AKT activity, which was, at least in part, based on a reduction of membrane phospholipid production (47). A previous study by our group
also supported the notion that inhibition of FASN suppresses the AKT pathway (11). However, to date, the effects of FASN on BTCC-cell migration and the possible involvement of the PI3K/AKT pathway or MMPs has remained elusive. The present study, showed that FASN inhibition downregulated MMP-9 expression by targeting the AKT pathway in BTCC cells to reduce cell migration. Thus, the present study not only provided further evidence for FASN inhibition being a promising therapeutic approach to control bladder-cancer invasion and metastasis, but also revealed the underlying mechanism via the PI3K/AKT pathway and MMP-9.

The present study provided further evidence that FASN has an important role in BTCC. FASN inhibition suppressed the migratory capacity of BTCC cells through downregulating MMP-9 expression; furthermore, the PI3K/AKT signaling pathway was indicated to be involved. These findings may enhance the understanding of the underlying mechanisms of the inhibitory effects of FASN knockdown on the migratory capacity of BTCC cells, and suggested that targeting FASN may be a potential therapeutic strategy for BTCC.

References


